BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
Bristol Myers Squibb and BioNTech announced first data from the Phase 2 ROSETTA Lung-107 trial of pumitamig plus docetaxel in second-line metastatic NSCLC, presented as a late-breaker at ESMO 2026. Among 30 efficacy-evaluable patients, the combination showed a confirmed objective response rate of 36.7% and disease control rate of 90.0%, with median PFS of 6.9 months versus roughly 3.6-3.9 months historically for standard-of-care docetaxel. Responses were consistent across PD-L1 expression levels and both squamous and non-squamous histologies, with a manageable safety profile and no new safety signals in 50 patients.
Key figures
- Drug Name
- pumitamig (BNT327/BMS986545)
- Phase Of Trial
- Phase 2
- Confirmed orr
- 36.7%
- Grade3 trae rate
- 18.0%
- Patients treated
- 50
- Median pfs months
- 6.9
- Six month pfs rate
- 63.3%
- Disease control rate
- 90.0%
- Median followup weeks
- 12.2
- Patients efficacy evaluable
- 30
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.